Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Ocular Therapeutix, Inc. (OCUL : NSDQ)
 
 • Company Description   
Ocular Therapeutix, Inc. is a biopharmaceutical company. It is focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. The Company develops and markets eye care products. Ocular Therapeutix, Inc. is headquartered in Bedford, Massachusetts.

Number of Employees: 274

 
 • Price / Volume Information   
Yesterday's Closing Price: $11.08 Daily Weekly Monthly
20 Day Moving Average: 2,225,221 shares
Shares Outstanding: 159.30 (millions)
Market Capitalization: $1,765.04 (millions)
Beta: 1.43
52 Week High: $11.78
52 Week Low: $5.79
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 23.80% 19.16%
12 Week 51.57% 27.49%
Year To Date 29.74% 21.50%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
15 CROSBY DRIVE
-
BEDFORD,MA 01730
USA		 ph: 781-357-4000
fax: 781-357-4001		 bslattery@ocutx.com http://www.ocutx.com
 
 • General Corporate Information   
Officers
Pravin Dugel - Executive Chairman of the Board of Directors; Pres
Donald Notman - Chief Financial Officer and Chief Operating Office
Adrienne Graves - Director
Seung Suh Hong - Director
Richard L. Lindstrom - Director

Peer Information
Ocular Therapeutix, Inc. (GSAC)
Ocular Therapeutix, Inc. (CASI)
Ocular Therapeutix, Inc. (ALCD.)
Ocular Therapeutix, Inc. (OMNN)
Ocular Therapeutix, Inc. (CGPI.)
Ocular Therapeutix, Inc. (CATX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 67576A100
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/06/25
Share - Related Items
Shares Outstanding: 159.30
Most Recent Split Date: (:1)
Beta: 1.43
Market Capitalization: $1,765.04 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.34 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.42 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: 5.18% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/06/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 6.64
Price/Cash Flow: -
Price / Sales: 29.59
EPS Growth
vs. Year Ago Period: -54.17%
vs. Previous Quarter: -27.59%
Sales Growth
vs. Year Ago Period: -27.59%
vs. Previous Quarter: -37.38%
ROE
06/30/25 - -
03/31/25 - -59.92
12/31/24 - -45.44
ROA
06/30/25 - -
03/31/25 - -41.98
12/31/24 - -32.94
Current Ratio
06/30/25 - -
03/31/25 - 10.22
12/31/24 - 10.66
Quick Ratio
06/30/25 - -
03/31/25 - 10.14
12/31/24 - 10.59
Operating Margin
06/30/25 - -
03/31/25 - -329.24
12/31/24 - -259.02
Net Margin
06/30/25 - -
03/31/25 - -323.09
12/31/24 - -303.67
Pre-Tax Margin
06/30/25 - -
03/31/25 - -323.09
12/31/24 - -303.67
Book Value
06/30/25 - -
03/31/25 - 1.67
12/31/24 - 2.01
Inventory Turnover
06/30/25 - -
03/31/25 - 1.98
12/31/24 - 2.13
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.26
12/31/24 - 0.22
Debt-to-Capital
06/30/25 - -
03/31/25 - 20.65
12/31/24 - 17.85
 

Powered by Zacks Investment Research ©